Skip to main content
. Author manuscript; available in PMC: 2015 Sep 1.
Published in final edited form as: Cell Microbiol. 2014 Jun 2;16(9):1441–1455. doi: 10.1111/cmi.12305

Fig. 4. Src is required for full Erk 1/2 activation and IL-8 secretion.

Fig. 4

Panels: (A) INT 407 cells were treated with PP2 and erlotinib to inhibit Src and the EGFR, respectively. Vehicle treated cells infected with C. jejuni served as a positive control and uninfected cells served as a negative control. Secreted IL-8 was quantified by ELISA. (B) INT 407 cells were treated with PP2 and erlotinib to inhibit Src and the EGFR, respectively. Erk 1/2 phosphorylation (activation) following a 30 min infection was measured by immunoblot using antibodies against phospho-Erk 1/2 (pErk). The membranes were re-probed using antibody against total Erk 1/2 (tErk) as a loading control. Densitometric analysis was used to quantify the level of pErk activation. (C) INT 407 cells were transfected with siRNA specific to p130Cas or scrambled siRNA (control). Non-transfected cells infected with C. jejuni served as a positive control and untreated cells served as a negative control. The efficiency of p130Cas knockdown was determined by immunoblot analysis. The membranes were re-probed using antibody against actin as a loading control.